Published in Clinical Trials Week, March 21st, 2005
According to a study from North Ireland, "the orally bioavailable matrix metalloproteinase inhibitor MMI270 reduces tumor growth metastasis in preclinical models. We assessed the feasibility and pharmacokinetic interactions of combining MMI270 with 5-fluorouracil (5-FU) and folinic acid (FA). Entered into the study were 33 patients with advanced colorectal cancer."
"They received FA 200 mg/m2 over 2 hours followed by 5-FU 400 mg/m2 over 15 min and 5-FU 600 mg/m2 over 22 hours on days 1 and 2 of a 14-day cycle. MMI270 commenced with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.